Despite various treatment protocols and newly recognized therapeutics,there are no effective treatment approaches against coronavirus disease.New therapeutic strategies including the use of stem cells-derived secretom...Despite various treatment protocols and newly recognized therapeutics,there are no effective treatment approaches against coronavirus disease.New therapeutic strategies including the use of stem cells-derived secretome as a cell-free therapy have been recommended for patients with critical illness.The pro-regenerative,pro-angiogenic,anti-inflammatory,anti-apoptotic,immunomodulatory,and trophic properties of stem cells-derived secretome,extracellular vesicles(EVs),and bioactive factors have made them suitable candidates for respiratory tract regeneration in coronavirus disease 2019(COVID-19)patients.EVs including microvesicles and exosomes can be applied for communication at the intercellular level due to their abilities in the long-distance transfer of biological messages such as mRNAs,growth factors,transcription factors,microRNAs,and cytokines,and therefore,simulate the specifications of the parent cell,influencing target cells upon internalization and/or binding.EVs exhibit both anti-inflammatory and tolerogenic immune responses by regulation of proliferation,polarization,activation,and migration of different immune cells.Due to effective immunomodulatory and high safety including a minimum risk of immunogenicity and tumorigenicity,mesenchymal stem cell(MSC)-EVs are more preferable to MSC-based therapies.Thus,as an endogenous repair and inflammation-reducing agent,MSCEVs could be used against COVID-19 induced morbidity and mortality after further mechanistic and preclinical/clinical investigations.This review is focused on the therapeutic perspective of the secretome of stem cells in alleviating the cytokine storm and organ injury in COVID-19 patients.展开更多
文摘Despite various treatment protocols and newly recognized therapeutics,there are no effective treatment approaches against coronavirus disease.New therapeutic strategies including the use of stem cells-derived secretome as a cell-free therapy have been recommended for patients with critical illness.The pro-regenerative,pro-angiogenic,anti-inflammatory,anti-apoptotic,immunomodulatory,and trophic properties of stem cells-derived secretome,extracellular vesicles(EVs),and bioactive factors have made them suitable candidates for respiratory tract regeneration in coronavirus disease 2019(COVID-19)patients.EVs including microvesicles and exosomes can be applied for communication at the intercellular level due to their abilities in the long-distance transfer of biological messages such as mRNAs,growth factors,transcription factors,microRNAs,and cytokines,and therefore,simulate the specifications of the parent cell,influencing target cells upon internalization and/or binding.EVs exhibit both anti-inflammatory and tolerogenic immune responses by regulation of proliferation,polarization,activation,and migration of different immune cells.Due to effective immunomodulatory and high safety including a minimum risk of immunogenicity and tumorigenicity,mesenchymal stem cell(MSC)-EVs are more preferable to MSC-based therapies.Thus,as an endogenous repair and inflammation-reducing agent,MSCEVs could be used against COVID-19 induced morbidity and mortality after further mechanistic and preclinical/clinical investigations.This review is focused on the therapeutic perspective of the secretome of stem cells in alleviating the cytokine storm and organ injury in COVID-19 patients.
